Masugi et al. reported that 78% of stromal cells expressed PD-L2, and 51.6% of tumor cells expressed PD-L233, while Guo et al. indicated 17.4% of immune cells expressed PD-L2 and 19.3% of tumor cells expressed PD-L2 in CRC44. The gene discussed is PDCD1LG2; the disease is neoplasm.